Please login to the form below

Not currently logged in
Email:
Password:

WuXi closes IPO

WuXi PharmaTech closes its initial public offering of 15,167,326 American Depositary Shares, including 1,978,347 ADSs issued in connection with the exercise of the over-allotment option in full

WuXi PharmaTech, a Chinese-headquartered pharmaceutical and biotechnology R&D outsourcing company has closed its initial public offering (IPO) of 15,167,326 American Depositary Shares ("ADSs"), including 1,978,347 ADSs issued in connection with the exercise of the over-allotment option in full.

WuXi PharmaTech's commenced trading on the New York Stock Exchange on 9 August 2007 under the symbol "WX". The US Securities and Exchange Commission (SEC) declared WuXi PharmaTech's registration statement effective.

Credit Suisse Securities (USA) and JP Morgan Securities acted as lead underwriters and joint book-runners and Jefferies & Company was co-manager in the offering.

15th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics